Although MIF is glycated in the control samples, the clear difference in the migratory behaviour of MIF identified from mild as well as severe AD samples indicate a modification specific to AD which first occurs during the early stages (Braak II) of the disease. The gene discussed is MIF; the disease is Alzheimer disease.